Akiyama, S.; Oda, K.; Mizohata, H.; Sasakura, N.; Hashimoto, K.; Maruoka, H.
Comparison of the Risk of Pneumonia Between Fluticasone Furoate/Umeclidinium/Vilanterol and Multiple-Inhaler Triple Therapy in Patients with COPD Using Health Insurance Claims Data: Final Analysis of Post-Marketing Database Surveillance in Japan. J. Clin. Med. 2025, 14, 4697.
https://doi.org/10.3390/jcm14134697
AMA Style
Akiyama S, Oda K, Mizohata H, Sasakura N, Hashimoto K, Maruoka H.
Comparison of the Risk of Pneumonia Between Fluticasone Furoate/Umeclidinium/Vilanterol and Multiple-Inhaler Triple Therapy in Patients with COPD Using Health Insurance Claims Data: Final Analysis of Post-Marketing Database Surveillance in Japan. Journal of Clinical Medicine. 2025; 14(13):4697.
https://doi.org/10.3390/jcm14134697
Chicago/Turabian Style
Akiyama, Shoko, Kenji Oda, Hiroko Mizohata, Natsuki Sasakura, Kenichi Hashimoto, and Hiroki Maruoka.
2025. "Comparison of the Risk of Pneumonia Between Fluticasone Furoate/Umeclidinium/Vilanterol and Multiple-Inhaler Triple Therapy in Patients with COPD Using Health Insurance Claims Data: Final Analysis of Post-Marketing Database Surveillance in Japan" Journal of Clinical Medicine 14, no. 13: 4697.
https://doi.org/10.3390/jcm14134697
APA Style
Akiyama, S., Oda, K., Mizohata, H., Sasakura, N., Hashimoto, K., & Maruoka, H.
(2025). Comparison of the Risk of Pneumonia Between Fluticasone Furoate/Umeclidinium/Vilanterol and Multiple-Inhaler Triple Therapy in Patients with COPD Using Health Insurance Claims Data: Final Analysis of Post-Marketing Database Surveillance in Japan. Journal of Clinical Medicine, 14(13), 4697.
https://doi.org/10.3390/jcm14134697